Tango Therapeutics (NASDAQ:TNGX) Shares Down 5.6% - Here's What Happened

Key Points

• Tango Therapeutics shares fell 5.6% to about $22.18 in mid-day trading, with volume down 84% from the average daily level.
• Analysts remain broadly positive, with a consensus “Moderate Buy” rating and an average price target of $43.46, despite one firm issuing a “Strong Sell” rating.
• The company reported quarterly EPS of -$0.37, missing the consensus estimate of -$0.32; analysts expect a full-year loss of approximately $1.41 per share.

Tango Therapeutics, Inc. (NASDAQ:TNGX - Get Free Report)'s stock price fell 5.6% during mid-day trading on Friday . The stock traded as low as $22.21 and last traded at $22.18. Approximately 549,213 shares changed hands during trading, a decline of 84% from the average daily volume of 3,338,186 shares. The stock had previously closed at $23.49.

Wall Street Analyst Weigh In

Several equities research analysts have recently weighed in on the company. JPMorgan Chase & Co. assumed coverage on Tango Therapeutics in a research note on Wednesday, July 15th. They issued an "overweight" rating and a $46.00 price target for the company. Mizuho boosted their price objective on Tango Therapeutics from $36.00 to $40.00 and gave the stock an "outperform" rating in a report on Friday, July 17th. Wolfe Research set a $35.00 price objective on shares of Tango Therapeutics and gave the stock an "outperform" rating in a report on Monday, June 8th. Wall Street Zen cut shares of Tango Therapeutics from a "sell" rating to a "strong sell" rating in a research report on Saturday, August 15th. Finally, Canaccord Genuity Group boosted their target price on Tango Therapeutics from $42.00 to $46.00 and gave the stock a "buy" rating in a research note on Monday, June 29th. Thirteen research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, Tango Therapeutics currently has a consensus rating of "Moderate Buy" and an average price target of $43.46.

Tango Therapeutics Trading Down 5.8%

The firm has a market cap of $3.73 billion, a P/E ratio of -26.05 and a beta of 1.12. The stock's fifty day moving average is $25.83 and its two-hundred day moving average is $24.26.

Tango Therapeutics (NASDAQ:TNGX - Get Free Report) last announced its earnings results on Tuesday, August 11th. The company reported ($0.37) earnings per share for the quarter, missing analysts' consensus estimates of ($0.32) by ($0.05). On average, analysts forecast that Tango Therapeutics, Inc. will post -1.41 EPS for the current year.

Insider Activity at Tango Therapeutics

In related news, insider Adam Crystal sold 27,000 shares of the firm's stock in a transaction dated Wednesday, July 1st. The stock was sold at an average price of $29.59, for a total transaction of $798,930.00. Following the transaction, the insider directly owned 115,743 shares of the company's stock, valued at approximately $3,424,835.37. This trade represents a 18.92% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this link. Company insiders own 6.50% of the company's stock.

Institutional Trading of Tango Therapeutics

Several hedge funds and other institutional investors have recently bought and sold shares of the company. Tidal Investments LLC purchased a new position in shares of Tango Therapeutics during the second quarter worth approximately $1,731,000. Allworth Financial LP boosted its stake in shares of Tango Therapeutics by 100.9% in the 2nd quarter. Allworth Financial LP now owns 1,131 shares of the company's stock valued at $35,000 after purchasing an additional 568 shares in the last quarter. Arizona State Retirement System boosted its stake in shares of Tango Therapeutics by 110.9% in the 2nd quarter. Arizona State Retirement System now owns 25,785 shares of the company's stock valued at $806,000 after purchasing an additional 13,561 shares in the last quarter. Nykredit A S bought a new position in shares of Tango Therapeutics during the 2nd quarter valued at $26,000. Finally, Allianz Asset Management GmbH bought a new position in shares of Tango Therapeutics during the 2nd quarter valued at $656,000. Hedge funds and other institutional investors own 78.99% of the company's stock.

About Tango Therapeutics

Tango Therapeutics, Inc is a biotechnology company focused on discovering and developing medicines that target cancer vulnerabilities. The company uses genetic screening, functional genomics and drug-discovery technologies to identify cancer-specific dependencies that may be addressed with targeted therapies.

Tango's research activities center on precision oncology and immuno-oncology, including programs designed to selectively eliminate tumor cells or improve the ability of the immune system to recognize and attack cancer.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.